7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Bénard J | [From metastatic osteolysis a painful message: beginning to understand with osteoprotegerin? | 2000 | Bull Cancer | pmid:11184451 |
Yamashita T et al. | Retardation in bone resorption after bone marrow ablation in klotho mutant mice. | 2000 | Endocrinology | pmid:10614667 |
Hofbauer LC et al. | The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. | 2000 | J. Bone Miner. Res. | pmid:10646108 |
Kanzawa M et al. | Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. | 2000 | Eur. J. Endocrinol. | pmid:10822231 |
Mukohyama H et al. | The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10777696 |
Atkins GJ et al. | Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. | 2000 | J. Bone Miner. Res. | pmid:10780856 |
Thompson SW and Tonge D | Bone cancer gain without the pain. | 2000 | Nat. Med. | pmid:10802700 |
Honore P et al. | Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. | 2000 | Nat. Med. | pmid:10802707 |
Onyia JE et al. | In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. | 2000 | J. Bone Miner. Res. | pmid:10804015 |
Bateman TA et al. | Osteoprotegerin mitigates tail suspension-induced osteopenia. | 2000 | Bone | pmid:10773583 |
Malyankar UM et al. | Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. | 2000 | J. Biol. Chem. | pmid:10811631 |
Thirunavukkarasu K et al. | The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. | 2000 | J. Biol. Chem. | pmid:10833509 |
Aubin JE and Bonnelye E | Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. | 2000 | Medscape Womens Health | pmid:10792853 |
Fata JE et al. | The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. | 2000 | Cell | pmid:11051546 |
Miyamoto N et al. | Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells. | 2000 | J. Orthop. Res. | pmid:11052502 |
Kinpara K et al. | Osteoclast differentiation factor in human osteosarcoma cell line. | 2000 | J Immunoassay | pmid:11071251 |
Kong YY et al. | Osteoprotegerin ligand: a regulator of immune responses and bone physiology. | 2000 | Immunol. Today | pmid:11071528 |
Kobayashi Y et al. | Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. | 2000 | J. Bone Miner. Res. | pmid:11028444 |
Kaneda T et al. | Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. | 2000 | J. Immunol. | pmid:11035059 |
Miyamoto T et al. | An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. | 2000 | Blood | pmid:11110710 |
Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. | 2000 | Bone | pmid:11113385 | |
Takayanagi H et al. | T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. | 2000 | Nature | pmid:11117749 |
Mancini L et al. | Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. | 2000 | Biochem. Biophys. Res. Commun. | pmid:11118297 |
Shalhoub V et al. | Characterization of osteoclast precursors in human blood. | 2000 | Br. J. Haematol. | pmid:11122091 |
Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. | 2000 | J. Bone Miner. Res. | pmid:11127193 | |
Sakuma Y et al. | Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. | 2000 | Infect. Immun. | pmid:11083800 |
Riggs BL | The mechanisms of estrogen regulation of bone resorption. | 2000 | J. Clin. Invest. | pmid:11086020 |
Udagawa N et al. | Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. | 2000 | Endocrinology | pmid:10965921 |
Yasuda H | [A new paradigm of osteoclast biology: discovery of OCIF and ODF]. | 2000 | Seikagaku | pmid:10967683 |
Teitelbaum SL | Bone resorption by osteoclasts. | 2000 | Science | pmid:10968780 |
Lacey DL et al. | Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. | 2000 | Am. J. Pathol. | pmid:10934148 |
Quinn JM et al. | Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. | 2000 | J. Bone Miner. Res. | pmid:10934644 |
Min H et al. | Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. | 2000 | J. Exp. Med. | pmid:10952716 |
Shiba H et al. | Effects of ageing on proliferative ability, and the expressions of secreted protein, acidic and rich in cysteine (SPARC) and osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human periodontal ligament cells. | 2000 | Mech. Ageing Dev. | pmid:10958924 |
López FJ | New approaches to the treatment of osteoporosis. | 2000 | Curr Opin Chem Biol | pmid:10959765 |
Nakashima T et al. | Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10973797 |
Itoh K et al. | Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. | 2000 | J. Bone Miner. Res. | pmid:10976996 |
Schinke T and Karsenty G | Vascular calcification--a passive process in need of inhibitors. | 2000 | Nephrol. Dial. Transplant. | pmid:10978374 |
Lorenzo J | Interactions between immune and bone cells: new insights with many remaining questions. | 2000 | J. Clin. Invest. | pmid:10995785 |
Teng YT et al. | Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. | 2000 | J. Clin. Invest. | pmid:10995794 |
Børset M et al. | Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. | 2000 | Blood | pmid:11001907 |
Hofbauer LC and Heufelder AE | Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. | 2000 | J. Clin. Endocrinol. Metab. | pmid:10902778 |
Rani CS and MacDougall M | Dental cells express factors that regulate bone resorption. | 2000 | Mol. Cell Biol. Res. Commun. | pmid:10860862 |
Tsurukai T et al. | Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. | 2000 | J. Bone Miner. Metab. | pmid:10874596 |
Günther T and Schinke T | Mouse genetics have uncovered new paradigms in bone biology. | 2000 | Trends Endocrinol. Metab. | pmid:10856921 |
Huang L et al. | Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. | 2000 | Am. J. Pathol. | pmid:10702390 |
Capparelli C et al. | Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. | 2000 | Cancer Res. | pmid:10706080 |
Makhluf HA et al. | Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10679262 |
Merewether LA et al. | Development of disulfide peptide mapping and determination of disulfide structure of recombinant human osteoprotegerin chimera produced in Escherichia coli. | 2000 | Arch. Biochem. Biophys. | pmid:10683254 |
Ross FP | RANKing the importance of measles virus in Paget's disease. | 2000 | J. Clin. Invest. | pmid:10712423 |
Tricot G | New insights into role of microenvironment in multiple myeloma. | 2000 | Lancet | pmid:10675068 |
Chikatsu N et al. | Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10631114 |
Takami M et al. | Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. | 2000 | Endocrinology | pmid:11108286 |
Gori F et al. | The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. | 2000 | Endocrinology | pmid:11108292 |
Clohisy DR et al. | Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. | 2000 | J. Orthop. Res. | pmid:11192258 |
Aubin JE and Bonnelye E | Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. | 2000 | Osteoporos Int | pmid:11193242 |
Wise GE et al. | Osteoprotegerin and osteoclast differentiation factor in tooth eruption. | 2000 | J. Dent. Res. | pmid:11201042 |
Kotake S et al. | [Molecular mechanism of bone metabolism]. | 2000 | Nippon Naika Gakkai Zasshi | pmid:11215116 |
Kanematsu M et al. | [Clinostat rotation culture modulates gene expression of osteoclastogenesis-regulating factors via a cyclic-AMP dependent mechanism]. | 2000 | Biol. Sci. Space | pmid:12561872 |
Saika M et al. | 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. | 2001 | Endocrinology | pmid:11356664 |
Mackie PS et al. | Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. | 2001 | Br. J. Cancer | pmid:11286476 |
Hofbauer LC et al. | Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis. | 2001 | J. Rheumatol. | pmid:11327234 |
Hofbauer LC and Heufelder AE | The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. | 2001 | Arthritis Rheum. | pmid:11229454 |
Leach RJ et al. | The genetics of Paget's disease of the bone. | 2001 | J. Clin. Endocrinol. Metab. | pmid:11231972 |
Luger NM et al. | Osteoprotegerin diminishes advanced bone cancer pain. | 2001 | Cancer Res. | pmid:11358823 |
Zhang J et al. | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. | 2001 | J. Clin. Invest. | pmid:11375413 |
Kostenuik PJ and Shalhoub V | Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. | 2001 | Curr. Pharm. Des. | pmid:11375772 |
Thirunavukkarasu K et al. | Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. | 2001 | J. Biol. Chem. | pmid:11451955 |
Sasaki N et al. | Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. | 2001 | Nephrol. Dial. Transplant. | pmid:11239019 |
Takeuchi T et al. | Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. | 2001 | Biochem. Pharmacol. | pmid:11239501 |
Mori K et al. | Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. | 2001 | Cell. Immunol. | pmid:11243701 |
Hofbauer LC et al. | Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11162519 |
Brändström H et al. | Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11162596 |
Wuyts W et al. | Evaluation of the role of RANK and OPG genes in Paget's disease of bone. | 2001 | Bone | pmid:11165949 |
Michigami T et al. | Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. | 2001 | Cancer Res. | pmid:11245477 |
Wada N et al. | Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. | 2001 | J. Periodont. Res. | pmid:11246705 |
Jung K et al. | Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. | 2001 | Clin. Chem. | pmid:11673385 |
Lean JM et al. | FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. | 2001 | Blood | pmid:11675341 |
Fiumara P et al. | Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. | 2001 | Blood | pmid:11675352 |
Pearse RN et al. | Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11562486 |
Kostenuik PJ et al. | OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. | 2001 | Endocrinology | pmid:11564687 |
Marco-Mingot M et al. | Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. | 2001 | Clin. Genet. | pmid:11531977 |
Raffai RL et al. | Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11553788 |
Hocking LJ et al. | Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. | 2001 | Am. J. Hum. Genet. | pmid:11555792 |
Hofbauer LC et al. | Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. | 2001 | Cancer | pmid:11505389 |
Hofbauer LC and Heufelder AE | Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. | 2001 | J. Mol. Med. | pmid:11485016 |
Furuya D et al. | Immuno-PCR assay for homodimeric osteoprotegerin. | 2001 | Clin. Chem. | pmid:11468243 |
Seck T et al. | Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. | 2001 | Eur. J. Endocrinol. | pmid:11454517 |
Burguera B et al. | Leptin reduces ovariectomy-induced bone loss in rats. | 2001 | Endocrinology | pmid:11459801 |
Yamagishi T et al. | Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. | 2001 | Endocrinology | pmid:11459812 |
Halladay DL et al. | Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. | 2001 | J. Cell. Biochem. | pmid:11746511 |
Cao Y et al. | IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. | 2001 | Cell | pmid:11747812 |
Chung H et al. | Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. | 2001 | J. Korean Med. Sci. | pmid:11748360 |
Komuro H et al. | The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. | 2001 | Arthritis Rheum. | pmid:11762937 |
Fukagawa M et al. | [PTH and bone metabolism in chronic dialysis patients]. | 2001 | Rinsho Byori | pmid:11307321 |
Horowitz MC et al. | Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. | 2001 | Cytokine Growth Factor Rev. | pmid:11312114 |
Lin DL et al. | Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. | 2001 | Prostate | pmid:11351351 |
Sparks AB et al. | Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. | 2001 | Calcif. Tissue Int. | pmid:11351498 |
Disthabanchong S and González EA | Regulation of bone cell development and function: implication for renal osteodystrophy. | 2001 | J. Investig. Med. | pmid:11352181 |
Kotake S et al. | Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. | 2001 | Arthritis Rheum. | pmid:11352231 |